Navigation Links
New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
Date:5/27/2008

de 1, and 12% were severe (grades 3 and 4). Partial or total recovery was observed within 18 months following treatment in most patients experiencing grade 3 peripheral sensory neuropathy. Patients treated with FOLFOX4 also reported nausea (73.7%), diarrhea (56.3%) and vomiting (47.2%).

"This announcement is welcome news for patients who have a significantly higher chance of surviving Stage III colon cancer when treated with the Eloxatin-based regimen following surgery," noted Dr. de Gramont. "Inclusion of these survival results in the new U.S. Eloxatin PI marks an important milestone in the treatment of colon cancer."

About MOSAIC

Eloxatin(R) in combination with infusional 5-FU/LV was first granted U.S. approval in 2004 for the treatment of Stage III colon cancer patients who have their primary tumors surgically removed based on the disease-free survival data from MOSAIC after a median follow-up of three years. At the time of the original analysis, there was no demonstrated benefit in overall survival after a median follow-up of four years.

Supported by sanofi-aventis, the phase III controlled MOSAIC trial was conducted in 148 centers in 20 countries. In MOSAIC, 2,246 patients with Stage II or Stage III colon cancer whose tumor had been completely surgically removed were randomized to treatment with either the Eloxatin-based FOLFOX4 regimen (n=1,123) or standard chemotherapy 5-FU/LV (n=1,123) every two weeks for 12 cycles. The primary endpoint evaluated how the addition of Eloxatin affected disease-free survival at three years. Secondary endpoints included overall survival and safety, including long-term adverse effects.

About Colorectal Cancer

Stage II colorectal cancer indicates that the cancer has grown through the wall of the colon or rectum but has not yet spread to nearby lymph nodes. At Stage III, the cancer has invaded one or more of the local lymph nodes but has not spread to distant sites. Metastatic colorectal ca
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. ORTHO EVRA(R) Prescribing Information Updated
6. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
9. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
10. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 VWR (NASDAQ: VWR ), ... announces the redesign of its global website, www.vwr.com , ... visiting the new site, guests will enjoy enhanced content on ... images.  Each country site now includes: , ... menu; and , the ability to search by discipline/industry. ...
(Date:8/3/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., ... call will cover an update on Merrimack,s progress as ... A press release detailing the information to be discussed ... Monday, August 10. Investors and the general public are ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. ... that once-daily naldemedine met its primary and secondary endpoints ... treatment of opioid-induced constipation (OIC) in adult patients with ... acting mu-opioid receptor antagonist (PAMORA). This is the third ... and key secondary endpoints. Study results showed ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... Orbitz Worldwide, Inc. (NYSE: OWW ) will host a conference call to ... on Wednesday, May 5, 2010 at 10:00 a.m. EDT ( 9:00 ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20070813/AQM125LOGO ) , ... A live webcast of the call can be accessed through the Orbitz Worldwide ...
... April 26 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced ... will present at Deutsche Bank,s 35th Annual Health Care Conference on Monday, ... InterContinental Boston Hotel in Boston, MA. , ... A live webcast of the presentation may be accessed from the ...
Cached Medicine Technology:Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 2Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 3
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years of marital bliss ... on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas lead the non-denominational ... the ceremony was a reception, with music by the Moonlight Serenade Orchestra and a ...
(Date:8/4/2015)... ... 2015 , ... Centurion Service Group, the world's largest medical equipment auction house, ... , The live auction will take place on Thursday, August 6 beginning ... at 5025 North Hiatus Road Sunrise, FL 33351. Anyone can participate in the auction ...
(Date:8/4/2015)... ... August 04, 2015 , ... Dr. Gary Richter, ... America’s Favorite Veterinarian. The contest is put on by the American Veterinary Medical ... nominees. Nominees were evaluated on community involvement, ethical behavior, passion for profession, and ...
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking ... the desire for invasive surgery to achieve this ideal is not. But minimally invasive ... crave without the high cost or lengthy recovery time, according to Valerie Goldburt, ...
(Date:8/4/2015)... ... August 04, 2015 , ... The Law Offices of Ben C. ... claims dealing with Inferior Vena Cava Filters (“IVC Filters”). , As lead IVC filter ... Cook IVC Filter clients under In re Cook Medical, Inc., IVC Filters Marketing, Sales ...
Breaking Medicine News(10 mins):Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Medical Equipment Auction to Take Place in Fort Lauderdale 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3
... , , , , ... The Ohio Nurses Association/Youngstown General Duty Nurses Association (ONA/YGDNA) ratified a ... process has resulted in the Registered Nurses of Northside Medical Center ... It is now up to the Forum Health management and ...
... , ANNAPOLIS, Md., July 27 ... company developing medical countermeasures against biological and chemical threats, today ... of 2-year, 10% unsecured senior convertible notes ("Notes") and common ... $19.3 million. , , In connection with ...
... BOZEN, Italy, July 27 Health Robotics today ... i.v.SOFT in order to market,implement, and support its I.V. ... infusion centers in North America. One of,its software modules ... at the University of Colorado Hospital [Denver], ...
... , , FRANKLIN LAKES, N.J., ... living in the country,s fifth largest city are now faced with ... Many commonly used therapy classes including drugs to treat diabetes, high ... in adults 20 and older. , , ...
... , , , Trinitas ... has new oral chemotherapy program in place ... availability of oral chemotherapy for treating a variety of cancers--along with projections ... drugs will be in oral form by 2013--raise questions for both clinicians ...
... , COLD SPRING HARBOR, N.Y., July 27 ... hand-held, non-contact vein illumination device, today announced that its quality ... Certification. This certifies to customers around the globe AccuVein,s commitment ... development, production, installation and delivery procedures. , ...
Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 2Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 2Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 4Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 2Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 3Health News:AccuVein Achieves Quality System Milestone 2
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides ... patient comfort. The latest in Fujinon ... increased light guide, and a wide 90 ... impressive 3.3mm distal tip diameter. In ...
German Style MacIntosh Fiber Optic Blade Laryngoscopes...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: